skip to Main Content
Written by: Vester Gravley on Thursday, August 20, 2015 Posted in:

“Alive! It’s alive! IT’S ALIVE!!!” (Dr. Frankenstein, pronounced FRONK-en-steen, in Young Frankenstein.)

A while ago, the FDA gave life to the Son of Advair, otherwise known as Breo Ellipta, the new face of COPD pharmaceuticals. The GSK website makes the following celebratory announcement:

“GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO™ ELLIPTA™ as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)…”

With Advair slated to go generic anytime, BREO™ ELLIPTA™ favorably positions GSK in the market. As a once-daily LAMA/LABA combination, BREO™ ELLIPTA™ could significantly improve patient medication compliance and reduce symptoms associated with COPD translating to better self management of their own disease state; potentially making improvements in quality of life and perhaps decreased ER visits and hospital admissions for these patients.

May we hale this new addition to the GSK family with another quote from the young Dr. Frankenstein; “Hello, handsome! You’re a good looking fellow, do you know that?